

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Oxytocin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Oxytocin Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 3447266-00015 Date of last issue: 04.12.2024
Date of first issue: 26.09.2018

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Oxytocin, monoacetate (salt)	6233-83-6 228-347-5	Acute Tox. 4; H302 Repr. 1A; H360D Aquatic Chronic 4; H413	$\geq 0,0002$ - $< 0,0025$

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

- Protection of first-aiders : No special precautions are necessary for first aid responders.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

5.3 Advice for firefighters

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Oxytocin, mono-acetate (salt)	6233-83-6	STEL	50 ng/m3 (OEB 5)	Internal
		Wipe limit	500 ng/100 cm ²	Internal

8.2 Exposure controls**Engineering measures**

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

(e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	No personal respiratory protective equipment normally required.

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight	:	No data available
Particle size	:	Not applicable

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Components:**Oxytocin, monoacetate (salt):**

	Acute oral toxicity	: LD50 (Mouse): > 514 mg/kg
		LD50 (Rat): > 21 mg/kg
	Acute toxicity (other routes of administration)	: LD50 (Mouse): > 514 mg/kg
		Application Route: Subcutaneous
		LD50 (Mouse): 5,8 mg/kg
		Application Route: Intravenous
	LD50 (Rat): > 21 mg/kg	
	Application Route: Subcutaneous	
	LD50 (Rat): 2,3 mg/kg	
	Application Route: Intravenous	

Skin corrosion/irritation

|| Not classified based on available information.

Serious eye damage/eye irritation

|| Not classified based on available information.

Respiratory or skin sensitisation**Skin sensitisation**

|| Not classified based on available information.

Respiratory sensitisation

|| Not classified based on available information.

Germ cell mutagenicity

|| Not classified based on available information.

Components:**Oxytocin, monoacetate (salt):**

	Genotoxicity in vitro	: Test Type: Chromosomal aberration
		Test system: Human lymphocytes
		Result: negative

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

||

Carcinogenicity

|| Not classified based on available information.

Reproductive toxicity

|| Not classified based on available information.

Components:**Oxytocin, monoacetate (salt):**

Effects on foetal development	:	Test Type: Development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 1 mg/kg body weight Result: No effects on foetal development
-------------------------------	---	---

Reproductive toxicity - Assessment	:	May damage the unborn child.
------------------------------------	---	------------------------------

STOT - single exposure

|| Not classified based on available information.

STOT - repeated exposure

|| Not classified based on available information.

Repeated dose toxicity**Components:****Oxytocin, monoacetate (salt):**

Species	:	Rat
LOAEL	:	5 µg/kg
Application Route	:	Subcutaneous
Exposure time	:	5 Days
Target Organs	:	Endocrine system

Aspiration toxicity

|| Not classified based on available information.

Experience with human exposure**Components:****Oxytocin, monoacetate (salt):**

Inhalation	:	Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract Symptoms: Nausea, Vomiting
Ingestion	:	Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018



Target Organs: Gastrointestinal tract
Symptoms: Nausea, Vomiting

SECTION 12: Ecological information**12.1 Toxicity****Components:**

Oxytocin, monoacetate (salt):

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential**Components:**

Oxytocin, monoacetate (salt):

Partition coefficient: n-octanol/water : log Pow: 6,27

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.4 Packing group

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA (Cargo)	: Not regulated as a dangerous good
IATA (Passenger)	: Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H360D : May damage the unborn child.

H413 : May cause long lasting harmful effects to aquatic life.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Ef-

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2024
3.0	14.04.2025	3447266-00015	Date of first issue: 26.09.2018

fect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN